BACKGROUND Lung carcinoma is the most common cause of cancer mortality worldwide. Most non-small cell lung carcinomas are inoperable and histologic diagnosis made on small biopsy samples are prone to diagnostic inaccuracy. So, precise subtyping of poorly differentiated non-small cell lung carcinoma (NSCLC) into adenocarcinoma and squamous cell carcinoma has a direct impact on management of patient and prognosis. The aim of this study was to investigate the role of immunohistochemistry profile using p63 and TTF-1 for differentiating nonsmall cell lung carcinoma into squamous cell carcinoma and adenocarcinoma. MATERIALS AND METHODS This descriptive study was conducted to assess p63 and TTF-1 expression in 80 cases of non-small cell lung carcinoma received in the Department of Pathology, Government Medical College, Kottayam during a period of 18 months (March 2016-September 2017). RESULTS Present study includes 80 cases of histologically diagnosed NSCLC. Of the study population, 73 cases (91.25%) were males and 7 cases (8.75%) were females. Among males, squamous cell carcinoma is the predominant histological subtype and adenocarcinoma is the predominant subtype in females. In this study, peak incidence is between 60-69 years of age. The mean age is 61 years. Out of the 80 histologically diagnosed cases of NSCLC studied, after IHC confirmation 47 were squamous cell carcinoma (58.75%), 27 were adenocarcinoma (38.75%), 3 were adenosquamous (3.75%) and rest 3 were NSCLC-NOS (3.75%). Histologically diagnosed cases of squamous cell carcinoma show 100% positivity for p63 and adenocarcinoma shows 100% positivity for TTF-1. CONCLUSION Both p63 and TTF-1 have 100% expression in squamous cell carcinoma and adenocarcinoma respectively. Hence, these markers may be recommended for subtyping of poorly differentiated non-small cell lung carcinoma (NSCLC).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.